Bill Maher

This is my understanding.

Someone will probably tell me I'm wrong, but that's my understanding.

Eli Lilly wants to protect the patent for Retatrutide, but I'll tell you, in Los Angeles County right now, there are a lot of people, mostly people that get in front of cameras, taking Retatrutide because it works so spectacularly well at a fifth of the prescribed dose or the recommended dose from these trials and at a tenth of the price if you get it from a compounding pharmacy.

Now, compounding pharmacies aren't supposed to make it, but this is another area where the FDA would like them to not do it, but it's pseudo-regulated.

The gray market, as I'm referring to it, is when people can buy this stuff online for research purposes only.

Then the black market, people refer to as Chinese peptides, which are peptides that probably don't contain what you think they do and there's very little stringency and you have to really worry about contamination.

It's a little unfair to China, I want to be clear.

These could be coming from Belarus for all I know.

They could be coming from anywhere, but people refer to them as Chinese peptides, which is not fair.

We should just call them black market peptides.

The FDA would like to protect its relationship to pharma.

Pharma wants to protect the patents for drugs where there's a lot of money.

Retrotrutide stands to be a trillion-dollar drug.

So here's the weird split.

I want to make sure I close the hatch on the FDA piece.

Right now, the key is to...

prevent harm, right?

We don't want people taking black market or gray market peptides that could hurt them.

At the same time, these compounding pharmacies have made many drugs, not just GLPs, but many drugs much more affordable to people in a landscape that I don't even have to justify, right?

People are really struggling for healthcare, self-directed healthcare,